About Indivumed, GmbH
Indivumed, GmbH: Your Resource for Precision Oncology
Indivumed, GmbH is a global oncology company that is dedicated to providing precision oncology solutions. The company was founded in 2002 by Dr. Hartmut Juhl and has since grown to become a leading provider of cancer research services.
At Indivumed, the focus is on personalized medicine and individualized cancer therapy. The company's mission is to improve the lives of cancer patients by providing accurate diagnoses and effective treatments based on each patient's unique genetic makeup.
One of the key strengths of Indivumed is its extensive biobank, which contains over 100,000 tissue samples from more than 20 different types of cancer. These samples are collected from consenting patients around the world and are used for research purposes to develop new therapies and diagnostic tools.
In addition to its biobank, Indivumed offers a range of other services that support precision oncology. These include molecular profiling, biomarker discovery, drug development support, and clinical trial management.
Molecular profiling involves analyzing a patient's tumor at the molecular level to identify specific genetic mutations or other abnormalities that may be driving tumor growth. This information can then be used to select targeted therapies that are more likely to be effective for that particular patient.
Biomarker discovery involves identifying new biomarkers – molecules in the body that can indicate the presence or progression of disease – through analysis of tissue samples from patients with different types of cancer. This information can then be used to develop new diagnostic tests or therapies.
Drug development support involves working with pharmaceutical companies or academic researchers who are developing new drugs for cancer treatment. Indivumed provides expertise in preclinical testing and clinical trial design as well as access to its biobank for drug screening purposes.
Clinical trial management involves overseeing all aspects of clinical trials – from study design through data analysis – in order to ensure their success. Indivumed has experience managing both early-phase (Phase I/II) trials as well as later-stage (Phase III/IV) trials.
Overall, Indivumed's commitment to precision oncology makes it an invaluable resource for researchers and clinicians alike who are working towards improving outcomes for cancer patients worldwide. With its extensive biobank and range of services supporting personalized medicine approaches such as molecular profiling and biomarker discovery; it stands out among other companies in this field making it one-of-a-kind!